分泌型卷曲相关蛋白4在肝细胞癌中的表达及其与患者临床病理指标和预后的关系

doi:10.3969/j.issn.1004-616x.2024.04.007

Abstract

Abstract: OBJECTIVE：To investigate expression of secreted frizzled-related protein 4 (sFRP4) in hepatocellular carcinoma (HCC) and relationship with clinicopathological index and prognosis. METHODS：Immunohistochemical methods were used to detect the expression of sFRP4 protein in 95 surgically resected HCC tissues and paracancerous tissues； patients clinicopathological indexes were used to analyze relationships with expression levels of the sFRP4 protein； the Kaplan-Meier survival curves were used to analyze relationships between expression of the sFRP4 protein and prognosis of the patients based on their clinicopathological index； and proportional hazards model (COX) was used to analyze factors affecting the prognosis of HCC patients. RESULTS：The positivity rate of sFRP4 protein was 48.42% (46/95) in HCC tissues and 85.26% (81/95) in paracancerous tissues. sFRP4 protein was therefore less positive in HCC tissues than in paracancerous tissues (χ²=24.596，P<0.01). Its expression in HCC tissues were significant for different histological grade (χ²=11.877，P<0.05)，histological subtype (χ²=3.873，P<0.05) and microvascular invasion (χ²=6.493，P<0.05). Patients with the sFRP4 protein-negativity had significantly worse cumulative overall survival (OS) and cumulative disease-free survival (PFS) than that of the positive group (both P<0.01). Cox multivariate analysis showed that sFRP4 protein [HR=0.238，95%CI(0.138，0.412)，P<0.01]，clinical stage of hepatocellular carcinoma in China [HR=2.438，95%CI(1.256，4.730)，P<0.01] were independent risk factors affecting the PFS after surgical resection of HCC. In addition，the sFRP4 protein [HR=0.226，95%CI(0.109，0.467)，P<0.01] and histological grade [HR=2.236，95%CI(1.199，4.170)，P<0.05] were independent risk factors affecting the OS after surgical resection of HCC. CONCLUSION：Expression levels of the sFRP4 protein were differentially significant between the HCC and paracancerous tissues，as well as with histological grade，histological subtype and microvascular invasion in HCC tissues. The sFRP4 protein-negative group of patients had a poorer prognosis. In addition，its expression level was an independent risk factor for the prognosis of these patients after surgical resection.

Key words: hepatocellular carcinoma, secreted frizzled-related protein 4, clinicopathological index, prognosis

CLC Number:

R730.2

ZHU Wenbiao, YAN Chunmei, QIU Bo, XIE Shoucheng, XIAO Huanqin, LIU Gaomin. Expression of secreted frizzled-related protein 4 in hepatocellular carcinoma, and relationship with clinicopathological index and prognosis[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(4): 288-293,297.

References

[1] XU X L, LIU X D, LIANG M, et al. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: systematic review of randomized controlled trials with metaanalysis and trial sequential analysis[J]. Radiology, 2018, 287(2): 461-472.
[2] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中华肝脏病杂志, 2022, 30(4): 367-388.
[3] 中华医学会肝病学分会. 原发性肝癌二级预防共识(2021年版)[J]. 中华肝脏病杂志, 2021, 29(3): 216-226.
[4] XING H, SUN L Y, YAN W T, et al. Repeat hepatectomy for patients with early and late recurrence of hepatocellular carcinoma: a multicenter propensity score matching analysis[J]. Surgery, 2021, 169(4): 911-920.
[5] DEV A Jr, VACHHER M, PRASAD C P. β-catenin inhibitors in cancer therapeutics: intricacies and way forward[J]. Bioengineered, 2023, 14(1): 2251696.
[6] VARIER L, SUNDARAM S M, GAMIT N, et al. An overview of ovarian cancer: the role of cancer stem cells in chemoresistance and a precision medicine approach targeting the Wnt pathway with the antagonist sFRP4[J]. Cancers, 2023, 15(4): 1275.
[7] SUNDARAM S M, VARIER L, FATHIMA K Z, et al. Short peptide domains of the Wnt inhibitor sFRP4 target ovarian cancer stem cells by neutralizing the Wnt β-catenin pathway, disrupting the interaction between β-catenin and CD24 and suppressing autophagy[J]. Life Sci, 2023, 316: 121384.
[8] TURAN, VITALE S G, KAHRAMANOGLU I, et al. Diagnostic and prognostic role of TFF3, Romo-1, NF-кB and SFRP4 as biomarkers for endometrial and ovarian cancers: a prospective observational translational study[J]. Arch Gynecol Obstet, 2022, 306(6): 2105-2114.
[9] BUSUTTIL R A, GEORGE J, HOUSE C M, et al. SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence [J]. Gastric Cancer, 2021, 24(3): 589-601.
[10] NFONSAM L E, JANDOVA J, JECIUS H C, et al. SFRP4 expression correlates with epithelial mesenchymal transitionlinked genes and poor overall survival in colon cancer patients [J]. World J Gastrointest Oncol, 2019, 11(8): 589-598.
[11] XU C, ZENG X H, WANG L, et al. sFRP-4, a potential novel serum marker for chronic hepatitis B-related hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int, 2015, 14(2): 164- 170.
[12] WU Q X, XU C, ZENG X H, et al. Tumor suppressor role of sFRP-4 in hepatocellular carcinoma via the Wnt/β-catenin signaling pathway[J]. Mol Med Rep, 2021, 23(5): 336.
[13] YANG M W, TAO L Y, YANG J Y, et al. SFRP4 is a prognostic marker and correlated with Treg cell infiltration in pancreatic ductal adenocarcinoma[J]. Am J Cancer Res, 2019, 9(2): 363-377.
[14] 黄滨, 王丽萍, 林宝泉. 食管鳞状细胞癌中SFRP4表达水平及临床意义[J]. 中国医药导报, 2022, 8(12): 13-16, 29.
[15] WU Z H, ZHANG Y J, YUE J X, et al. Comprehensive analysis of the expression and prognosis for SFRPs in breast carcinoma [J]. Cell Transplant, 2020, 29: 963689720962479.
[16] BELUR NAGARAJ A, KNARR M, SEKHAR S, et al. The miR- 181a-SFRP4 axis regulates Wnt activation to drive stemness and platinum resistance in ovarian cancer[J]. Cancer Res, 2021, 81(8): 2044-2055.
[17] GUO L W, CHEN H H, CHEN J G, et al. PBX1-promoted SFRP4 transcription inhibits cell proliferation and epithelial-mesenchymal transition in endometrial carcinoma[J]. Tissue Cell, 2023, 82: 102083.
[18] MASHHADIKHAN M, KHEIRI H, DEHGHANIFARD A. DNA methylation and gene expression of sFRP2, sFRP4, Dkk 1, and Wif1 during osteoblastic differentiation of bone marrow derived mesenchymal stem cells[J]. J Oral Biosci, 2020, 62(4): 349-356.
[19] MANDAL S, GAMIT N, VARIER L, et al. Inhibition of breast cancer stem-like cells by a triterpenoid, ursolic acid, via activation of Wnt antagonist, sFRP4 and suppression of miRNA-499a-5p[J]. Life Sci, 2021, 265: 118854.

Expression of secreted frizzled-related protein 4 in hepatocellular carcinoma, and relationship with clinicopathological index and prognosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	MA Sheng, WANG Xijun, LIU Zhenrong, WANG Yaru, HU Nan, RONG Weiqi, XIAO Ting. The expression and clinical significance of MFSD2A in hepatocellular carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(3): 187-194.
[2]	ZHANG Yi, GAO Han, ZHENG Zhanyue, TAN Qitao, YANG Minli, SUN Yan. Screening of key genes for prognosis of glioma based on public databases [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(3): 195-201.
[3]	SONG Zhenming, YU Yunliang, YANG Jinmei, LIU Kun, GAI Chanchan, MA Chunyu. Prognostic value of P2RX1 in patients with ovarian serous carcinoma and its role in immune infiltration mechanisms [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(3): 208-218.
[4]	FU Yongqing, XU Sanhui, ZHAO Yan, WANG Lili. Relationships between SPP1, DEC1, C1QTNF6 and clinicopathologic outcomes of oral squamous cell carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(2): 107-111,117.
[5]	TONG Jing, WANG Dan. Expression and significance of miR-544a in patients with colorectal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(2): 124-128,137.
[6]	XUE Song, HU Jiahai, DONG Xiangning. Expression of PGAM5 and its association with clinicopathologic characteristics in pancreatic cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 29-34.
[7]	WANG Kefang, CHEN Yu, WU Chenyu, LIU Mei, WANG Lijie, TIAN Jianguang, ZHOU Xiaohui, XU Lan. Clinicopathological roles of IL-17A and estrogen receptors α, β in epithelial ovarian cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 42-47.
[8]	ZHU Wenbiao, QIU bo, XIE Shoucheng, XIAO Huanqin, LIU Gaomin. Expression and clinical significance of transmembrane protein 79 in hepatocellular carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 426-430.
[9]	YANG Shangying, HUANG Mingxiang, XU Dexin, LIU Jiafu, CHEN Xinfu. Expression of DNAJB4 and association with immune infiltration and prognosis in non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 467-472.
[10]	GUO Wenjing, DENG Hui, SONG Ping, ZHANG Mengxian. Expression and biological functions of TGFBI in glioma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 341-348.
[11]	WEI Laifeng, HONG Chaoqun, CHEN Liuyi, XU Yiwei, WU Fangcai. Prognostic value of nomogram of laboratory inflammation-related indicators in tongue squamous cell carcinoma patients with surgery [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 366-373.
[12]	YANG Chengqing, CUI Yonghui, ZHENG Ziheng. Expression and clinical significance of miR-653-5p in colon cancer patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 261-265.
[13]	LIU Ruixue, ZHANG Liwei. Expression and significance of AMPK esophageal squamous cell carcinoma among Kazakhs [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 285-291.
[14]	LIU Ying, WANG Rui, GUO Xiao, DONG Lüli, ZHANG Yan, ZHAO Yinhuan, DU Yun. Relationships between DNA ploidy abnormality and EGFR mutation in pleural effusions, and their effects on prognosis of lung adenocarcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 178-182,186.
[15]	WANG Ping, WANG Huayong, WANG Hao, LEI Dajun. Expression of miR-193a and miR-21-5p in serum exosomes from osteosarcoma patients and their clinical values [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 197-201.